Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 194 of 5804
-
Can a new oral drug help tame leigh syndrome?
Disease control Not yet recruitingThe goal of this clinical trial is to investigate oral TTI-0102 to evaluate its pharmacokinetics, safety, and preliminary efficacy in patients with Leigh syndrome spectrum, in three sequences. First sequence will be placebo-controlled and include 12 adolescents and adults weighin…
Phase: PHASE2 • Sponsor: Thiogenesis Therapeutics, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New personalized safety plan aims to save Veterans' lives after hospital discharge
Symptom relief Not yet recruitingVeterans psychiatrically hospitalized face significantly elevated suicide risk, particularly in the three months post-discharge. While Safety Planning is a required component of discharge planning, many safety plans lack personalization thereby reducing their effectiveness. The p…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New scan spots hidden organ damage before symptoms start
Diagnosis Not yet recruitingThe goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits…
Phase: NA • Sponsor: University of Zurich • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Could common painkillers boost opioid effectiveness for cancer patients?
Symptom relief Not yet recruitingThe investigators investigate the efficacy of non-opioid analgesics compared to placebo together with opioid therapy for cancer pain management.
Phase: PHASE3 • Sponsor: University Hospital, Basel, Switzerland • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
Could a new drug replace steroids for brain tumor swelling?
Disease control Not yet recruitingThe purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a ste…
Phase: PHASE2 • Sponsor: Akshitkumar MIstry • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Personalized radiation pulses could boost esophageal cancer treatment
Disease control Not yet recruitingThe goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the safest dose of radiation that can be used. Participan…
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
Disease control Recruiting nowThis study is a prospective, multicenter, single-arm, open-label Phase II clinical trial, planned to enroll 30 patients with unresectable locally advanced or metastatic iCCA/GBC. Patients will first receive cryoablation treatment, and two weeks after ablation, they will receive 8…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo treatment aims to slash sepsis deaths in HIV patients
Disease control Not yet recruitingSepsis, a life-threatening condition due to a dysregulated response to infection, is the leading cause of global mortality and is frequently driven by tuberculosis (TB) and drug-resistant bacteria in sub-Saharan Africa, particularly among people living with HIV. The prevailing st…
Phase: PHASE3 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill aims to tame stubborn high blood pressure
Disease control Not yet recruitingThis is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average SBP in participants with uHTN. Consenting partici…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Implanted nerve stimulator aims to restore walking after spinal injury
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety, feasibility, and preliminary effectiveness of the ReWire system, which delivers vagus nerve stimulation (VNS) paired with lower limb rehabilitation to improve gait in individuals with mobility impairments resulting from chronic…
Phase: NA • Sponsor: The University of Texas at Dallas • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Digital sleep and mood programs put to the test for breast cancer survivors
Symptom relief Not yet recruitingCo-occurring symptoms of insomnia and depression is very common in breast cancer survivors, and it is critical that scalable and easily accessible digital behavioral interventions are made available. Digital health interventions are scalable and accessible. Moreover, behavioral d…
Phase: NA • Sponsor: University of Virginia • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
Could your own blood cells ease knee arthritis pain?
Disease control Not yet recruitingThe goal of this Phase II/III, double-blinded, multicenter clinical trial is to assess the clinical efficacy of autologous peripheral blood mononuclear cells (PBMCs) in the management of knee osteoarthritis (KOA). The main questions it aims to answer are: 1. To determine the saf…
Phase: PHASE2, PHASE3 • Sponsor: DuoGenic StemCells Corporation (DGSC) • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can a Bladder-Instilled biologic keep recurrent bladder cancer at bay?
Disease control Not yet recruitingThis study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).
Phase: PHASE1 • Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Promising combo aims to add months for deadly thyroid cancer patients
Disease control Not yet recruitingThe goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination. Given an accrual period of 24 months and a maximum follow-up time of 36 months, at the significance level of 0.1, to achieve the power of 0.8, the s…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a new drug free PAH patients from daily pump therapy?
Disease control Not yet recruitingPulmonary arterial hypertension (PAH) is a rare lung disease that leads to elevated blood pressure in the lungs and strain on the right side of the heart. For many years, treatments for PAH have included drugs that target the prostacyclin pathway using intravenous, subcutaneous, …
Phase: NA • Sponsor: University of Alberta • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Hope for rett syndrome: new drug trial targets behavior and communication
Symptom relief Recruiting nowPrimary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and wom…
Phase: PHASE3 • Sponsor: Biomed Industries, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail aims to supercharge weight loss in obesity trial
Disease control Not yet recruitingThe main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Weekly pill cocktail aims to tame resistant blood cancers
Disease control Not yet recruitingThis is a single-center randomized phase 2 open-label clinical trial.
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Drug combo aims to shrink Hard-to-Treat anal cancer
Disease control Not yet recruitingThe goal of this clinical trial is to see the safety and efficacy of pembrolizumab and lenvatinib in patients with anal squamous cell cancer that cannot be removed through surgery or is spread to other organs. Eligible participants should have also received some form of standard …
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Brain zaps boost therapy for PTSD in troops with head injuries
Symptom relief Not yet recruitingIn this study, the investigators are evaluating whether transcranial direct current stimulation (tDCS), a brain stimulation technique, can be combined with Written Exposure Therapy (WET), a standard talk therapy for posttraumatic stress disorder (PTSD) to improve treatment respon…
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC